GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at Replays of the webcasts will be available for at least 30 days following the events. Anaptys is ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis ...

Amit Shah vows anti-conversion law in Maharashtra, opposition caste census Union Home Minister Amit Shah, during the release of BJP's election manifesto in Mumbai, promised a stringent anti ...

Nov. 7, 2024 — Plastic pollution exacerbates the impacts of all planetary boundaries, including climate change, ocean acidification and biodiversity loss, a new paper shows. Ahead of the final ...

Nov. 7, 2024 — Plastic pollution exacerbates the impacts of all planetary boundaries, including climate change, ocean acidification and biodiversity loss, a new paper shows. Ahead of the final ...

CENTRAL GOVERNMENT FUNDS: Social welfare would account for the largest portion of the NT$3.33 trillion budget, followed by spending on education, tech and culture ...